TapewireFind a company

person · Reporting owner

Kemble George

Disclosed activity across 1 company

Tapewire entity
22811
SEC CIK
0001858176

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Sagimet Biosciences Inc.SGMT · Entity 5273DirectorAugust 14, 2026August 17, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Sagimet Biosciences Inc.

Report date August 14, 2026 · Filed August 17, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Series A Common StockSEC Table I · non-derivativeDirect62,161 Ending reported balance After 2026-08-14 transaction · row 3
3 source rows · reconciled sequence

Row 1 · 2026-08-14 · Exercise / conversion · Acquired 326,618 · Balance 388,779

F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

Row 2 · 2026-08-14 · Exercise / conversion · Acquired 24,369 · Balance 413,148

F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

Row 3 · 2026-08-14 · Sale · Disposed 350,987 · Balance 62,161

F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $10.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2029-04-27Direct31,455 Reported balance After 2026-08-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-08-14 · Exercise / conversion · Disposed 326,618 · Balance 31,455

F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

F3: This option is fully vested and exercisable as of the date hereof.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2029-04-27Direct11,608 Reported balance After 2026-08-14 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2026-08-14 · Exercise / conversion · Disposed 24,369 · Balance 11,608

F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

F3: This option is fully vested and exercisable as of the date hereof.

Filing footnotes · ownership attribution and instrument terms

F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $10.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: This option is fully vested and exercisable as of the date hereof.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 14, 2026 Filed Aug 17, 2026 20:05 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 Exercise / conversionStock Option (Right to Buy) · Derivative 24,369 $0.00 Strike: $6.36 $0.00
Disclosure

SEC source: 0001193125-26-354018 · ownership.xml · derivative · entry 5

Kemble George · CIK 0001858176 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,608

Underlying: Series A Common Stock · 24,369 shares

Expires 2029-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof.

Read SEC document
August 14, 2026 Filed Aug 17, 2026 20:05 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 Exercise / conversionStock Option (Right to Buy) · Derivative 326,618 $0.00 Strike: $6.36 $0.00
Disclosure

SEC source: 0001193125-26-354018 · ownership.xml · derivative · entry 4

Kemble George · CIK 0001858176 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,455

Underlying: Series A Common Stock · 326,618 shares

Expires 2029-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof.

Read SEC document
August 14, 2026 Filed Aug 17, 2026 20:05 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 SaleSeries A Common Stock 350,987 $10.23 $3,591,579.77
Disclosure

SEC source: 0001193125-26-354018 · ownership.xml · nonDerivative · entry 3

Kemble George · CIK 0001858176 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,161

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $10.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
August 14, 2026 Filed Aug 17, 2026 20:05 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 Exercise / conversionSeries A Common Stock 24,369 $6.36 $154,986.84
Disclosure

SEC source: 0001193125-26-354018 · ownership.xml · nonDerivative · entry 2

Kemble George · CIK 0001858176 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 413,148

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

Read SEC document
August 14, 2026 Filed Aug 17, 2026 20:05 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 Exercise / conversionSeries A Common Stock 326,618 $6.36 $2,077,290.48
Disclosure

SEC source: 0001193125-26-354018 · ownership.xml · nonDerivative · entry 1

Kemble George · CIK 0001858176 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 388,779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

Read SEC document
August 11, 2026 Filed Aug 12, 2026 23:41 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 Exercise / conversionStock Option (Right to Buy) · Derivative 10,455 $0.00 Strike: $6.36 $0.00
Disclosure

SEC source: 0001193125-26-347407 · ownership.xml · derivative · entry 5

Kemble George · CIK 0001858176 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,977

Underlying: Series A Common Stock · 10,455 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof.

F3 · derivative.expiration_date: This option is fully vested and exercisable as of the date hereof.

Read SEC document
August 11, 2026 Filed Aug 12, 2026 23:41 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 Exercise / conversionStock Option (Right to Buy) · Derivative 9,751 $0.00 Strike: $6.36 $0.00
Disclosure

SEC source: 0001193125-26-347407 · ownership.xml · derivative · entry 4

Kemble George · CIK 0001858176 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 358,073

Underlying: Series A Common Stock · 9,751 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof.

F3 · derivative.expiration_date: This option is fully vested and exercisable as of the date hereof.

Read SEC document
August 11, 2026 Filed Aug 12, 2026 23:41 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 SaleSeries A Common Stock 20,206 $9.95 $201,146.69
Disclosure

SEC source: 0001193125-26-347407 · ownership.xml · nonDerivative · entry 3

Kemble George · CIK 0001858176 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,161

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $9.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
August 11, 2026 Filed Aug 12, 2026 23:41 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 Exercise / conversionSeries A Common Stock 10,455 $6.36 $66,493.80
Disclosure

SEC source: 0001193125-26-347407 · ownership.xml · nonDerivative · entry 2

Kemble George · CIK 0001858176 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 82,367

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

Read SEC document
August 11, 2026 Filed Aug 12, 2026 23:41 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 Exercise / conversionSeries A Common Stock 9,751 $6.36 $62,016.36
Disclosure

SEC source: 0001193125-26-347407 · ownership.xml · nonDerivative · entry 1

Kemble George · CIK 0001858176 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 71,912

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

Read SEC document
July 20, 2026 Filed Jul 22, 2026 20:05 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 SaleSeries A Common Stock 18,844 $7.46 $140,529.13
Disclosure

SEC source: 0001193125-26-312386 · ownership.xml · nonDerivative · entry 1

Kemble George · CIK 0001858176 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,161

F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.17 to $7.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 12, 2026 Filed Jun 15, 2026 20:20 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 GrantStock Option (Right to Buy) · Derivative 39,567 $0.00 Strike: $6.48 $0.00
Disclosure

SEC source: 0001104659-26-074045 · tm2617570-2_4seq1.xml · derivative · entry 1

Kemble George · CIK 0001858176 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,567

Underlying: Series A Common Stock · 39,567 shares

Expires 2036-06-11

F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
November 20, 2025 Filed Nov 21, 2025 23:13 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 SaleSeries A Common Stock 37,688 $7.69 $289,979.01
Disclosure

SEC source: 0001104659-25-115071 · tm2531988-1_4seq1.xml · nonDerivative · entry 1

Kemble George · CIK 0001858176 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,005

F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.27 to $8.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 09, 2025 Filed Jun 10, 2025 21:40 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 GrantStock Option (Right to Buy) · Derivative 32,250 $0.00 Strike: $5.33 $0.00
Disclosure

SEC source: 0001104659-25-058223 · tm2517621-4_4seq1.xml · derivative · entry 1

Kemble George · CIK 0001858176 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,250

Underlying: Series A Common Stock · 32,250 shares

Expires 2035-06-08

F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
July 23, 2024 Filed Jul 25, 2024 20:05 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 SaleSeries A Common Stock 23,625 $3.17 $74,829.83
Disclosure

SEC source: 0001104659-24-082630 · tm2420121-1_4seq1.xml · nonDerivative · entry 1

Kemble George · CIK 0001858176 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 118,693

F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.07 to $3.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 19, 2024 Filed Jul 23, 2024 20:05 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 SaleSeries A Common Stock 14,062 $3.10 $43,604.86
Disclosure

SEC source: 0001104659-24-081887 · tm2420000-1_4.xml · nonDerivative · entry 1

Kemble George · CIK 0001858176 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,318

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

Read SEC document
November 17, 2023 Filed Nov 21, 2023 21:22 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 GrantSeries A Common Stock 150,750 $0.00 $0.00
Disclosure

SEC source: 0001104659-23-120374 · tm2331048-2_4seq1.xml · nonDerivative · entry 1

Kemble George · CIK 0001858176 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,380

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. 25% of the RSUs shall vest on July 18, 2024, with the remainder vesting in three equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
September 07, 2023 Filed Sep 8, 2023 20:15 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 Exercise / conversionStock Option (Right to Buy) · Derivative 5,630 $0.00 Strike: $0.79 $0.00
Disclosure

SEC source: 0001104659-23-099310 · tm2325723-1_4seq1.xml · derivative · entry 2

Kemble George · CIK 0001858176 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Series A Common Stock · 5,630 shares

Expires 2023-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof.

Read SEC document
September 07, 2023 Filed Sep 8, 2023 20:15 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 Exercise / conversionSeries A Common Stock 5,630 $0.79 $4,447.70
Disclosure

SEC source: 0001104659-23-099310 · tm2325723-1_4seq1.xml · nonDerivative · entry 1

Kemble George · CIK 0001858176 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,630

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:17 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 GrantStock Option (Right to Buy) · Derivative 21,173 $0.00 Strike: $7.15 $0.00
Disclosure

SEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 16

Kemble George · CIK 0001858176 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,173

Underlying: Series A Common Stock · 21,173 shares

Expires 2032-10-16

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F4 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on October 17, 2023, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:17 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 Disposition to issuerStock Option (Right to Buy) · Derivative 21,173 $0.00 Strike: $7.15 $0.00
Disclosure

SEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 15

Kemble George · CIK 0001858176 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,173 shares

Expires 2032-10-16

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F4 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on October 17, 2023, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:17 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 GrantStock Option (Right to Buy) · Derivative 526,332 $0.00 Strike: $6.36 $0.00
Disclosure

SEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 14

Kemble George · CIK 0001858176 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 526,332

Underlying: Series A Common Stock · 526,332 shares

Expires 2031-01-26

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F3 · derivative.exercise_date: The shares underlying this option vest and become exercisable in forty-eight (48) equal monthly installments following January 27, 2021, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:17 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 Disposition to issuerStock Option (Right to Buy) · Derivative 526,332 $0.00 Strike: $6.36 $0.00
Disclosure

SEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 13

Kemble George · CIK 0001858176 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 526,332 shares

Expires 2031-01-26

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F3 · derivative.exercise_date: The shares underlying this option vest and become exercisable in forty-eight (48) equal monthly installments following January 27, 2021, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:17 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 GrantStock Option (Right to Buy) · Derivative 46,432 $0.00 Strike: $6.36 $0.00
Disclosure

SEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 12

Kemble George · CIK 0001858176 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,432

Underlying: Series A Common Stock · 46,432 shares

Expires 2029-04-27

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof.

Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:17 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 Disposition to issuerStock Option (Right to Buy) · Derivative 46,432 $0.00 Strike: $6.36 $0.00
Disclosure

SEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 11

Kemble George · CIK 0001858176 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 46,432 shares

Expires 2029-04-27

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof.

Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:17 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 GrantStock Option (Right to Buy) · Derivative 367,824 $0.00 Strike: $6.36 $0.00
Disclosure

SEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 10

Kemble George · CIK 0001858176 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 367,824

Underlying: Series A Common Stock · 367,824 shares

Expires 2029-04-27

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof.

Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:17 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 Disposition to issuerStock Option (Right to Buy) · Derivative 367,824 $0.00 Strike: $6.36 $0.00
Disclosure

SEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 9

Kemble George · CIK 0001858176 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 367,824 shares

Expires 2029-04-27

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof.

Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:17 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 GrantStock Option (Right to Buy) · Derivative 26,352 $0.00 Strike: $19.87 $0.00
Disclosure

SEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 8

Kemble George · CIK 0001858176 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,352

Underlying: Series A Common Stock · 26,352 shares

Expires 2025-10-12

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof.

Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:17 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 Disposition to issuerStock Option (Right to Buy) · Derivative 26,352 $0.00 Strike: $19.87 $0.00
Disclosure

SEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 7

Kemble George · CIK 0001858176 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,352 shares

Expires 2025-10-12

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof.

Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:17 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 GrantStock Option (Right to Buy) · Derivative 7,147 $0.00 Strike: $23.05 $0.00
Disclosure

SEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 6

Kemble George · CIK 0001858176 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,147

Underlying: Series A Common Stock · 7,147 shares

Expires 2024-12-16

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof.

Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:17 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 Disposition to issuerStock Option (Right to Buy) · Derivative 7,147 $0.00 Strike: $23.05 $0.00
Disclosure

SEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 5

Kemble George · CIK 0001858176 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,147 shares

Expires 2024-12-16

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof.

Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:17 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 GrantStock Option (Right to Buy) · Derivative 3,179 $0.00 Strike: $11.13 $0.00
Disclosure

SEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 4

Kemble George · CIK 0001858176 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,179

Underlying: Series A Common Stock · 3,179 shares

Expires 2024-03-12

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof.

Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:17 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 Disposition to issuerStock Option (Right to Buy) · Derivative 3,179 $0.00 Strike: $11.13 $0.00
Disclosure

SEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 3

Kemble George · CIK 0001858176 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,179 shares

Expires 2024-03-12

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof.

Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:17 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 GrantStock Option (Right to Buy) · Derivative 5,630 $0.00 Strike: $0.79 $0.00
Disclosure

SEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 2

Kemble George · CIK 0001858176 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,630

Underlying: Series A Common Stock · 5,630 shares

Expires 2023-09-26

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof.

Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:17 UTC Sagimet Biosciences Inc. SGMT · Entity 5273 Disposition to issuerStock Option (Right to Buy) · Derivative 5,630 $0.00 Strike: $0.79 $0.00
Disclosure

SEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 1

Kemble George · CIK 0001858176 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,630 shares

Expires 2023-09-26

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.